Anebulo Pharmaceuticals, Inc. ANEB

expiry = 2026-01-26...Inc. OF UP TO 300,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $3.50 PER SHARE, REPRESENTING AN AGGREGATE PURCHASE PRICE OF UP TO $1,050,000 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON Monday, January 26, 2026, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION DATE”) OR earlier TERMINATED. Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company,” “Anebulo,” “we,” “our” or “us”), is offering to...

expiry = 2026-01-26...Inc. OF UP TO 300,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $3.50 PER SHARE, REPRESENTING AN AGGREGATE PURCHASE PRICE OF UP TO $1,050,000 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON Monday, January 26, 2026, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION DATE”) OR earlier TERMINATED. Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company,” “Anebulo,” “we,” “our” or “us”), is offering to...

listed = True...scribed above, we may be required to extend the Expiration Date. Any determination by us concerning the events described above will be final and binding on all parties. See Section 15. 8. Price Range of Shares; Dividends Price Range of Shares Our Common Stock is traded on Nasdaq under the symbol “ANEB.” The following table sets forth the high and low sales prices reported by Nasdaq for our Common Stock during the periods indicated: High ($) Low ($) Fiscal Year Ended June 30, 2023: First Quarter 7.00 2.78 Second Quarter 3.63 1.77 Third Quarter 3.43 2.24 Fourth Quarter 3.19 2.00 Fiscal Year Ended June 30, 2024: First Quarter 2.78 2...

listed = True...scribed above, we may be required to extend the Expiration Date. Any determination by us concerning the events described above will be final and binding on all parties. See Section 15. 8. Price Range of Shares; Dividends Price Range of Shares Our Common Stock is traded on Nasdaq under the symbol “ANEB.” The following table sets forth the high and low sales prices reported by Nasdaq for our Common Stock during the periods indicated: High ($) Low ($) Fiscal Year Ended June 30, 2023: First Quarter 7.00 2.78 Second Quarter 3.63 1.77 Third Quarter 3.43 2.24 Fourth Quarter 3.19 2.00 Fiscal Year Ended June 30, 2024: First Quarter 2.78 2...

mechanism = FIXEDEX-99 2 exa1-a.htm EX-99 Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH BY Anebulo Pharmaceuticals, Inc. OF UP TO 300,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $3.50 PER SHARE, REPRESENTING AN AGGREGATE PURCHASE PRICE OF UP TO $1,050,000 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON Monday, January 26, 2026, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION DATE”) OR earlier TERMINATED. Anebulo Pharm...

mechanism = FIXEDEX-99 2 exa1-a.htm EX-99 Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH BY Anebulo Pharmaceuticals, Inc. OF UP TO 300,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $3.50 PER SHARE, REPRESENTING AN AGGREGATE PURCHASE PRICE OF UP TO $1,050,000 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON Monday, January 26, 2026, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION DATE”) OR earlier TERMINATED. Anebulo Pharm...

mechanism = FIXED..., as amended and supplemented on January 8, 2026, and January 27, 2026 (as amended and supplemented, the “Schedule TO”) relating to the tender offer by the Company to purchase for cash up to 300,000 shares of its common stock, par value $0.001 per share, at a purchase price of $3.50 per share, to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal, copies of which were attached to the Schedule TO and which, together with any other related materials, as each may be amended or supplem...

must_tender_all = True...of such tendered Shares 300,000 or less are tendered by Odd Lot Holders (as defined below), we will purchase Shares on the following basis: ● first, we will purchase Odd Lots (as defined below) of fewer than 100 Shares at the Purchase Price from stockholders who properly tender all of their Shares and who do not properly withdraw them before the Expiration Date. Tenders of less than all of the Shares owned, beneficially or of record, by such Odd Lot Holder will not qualify for this preference; and ● second, after purchasing all Odd Lots that were properly tendered, we will purchase all Shares properly tendered on a pro rata basis...

must_tender_all = True...of such tendered Shares 300,000 or less are tendered by Odd Lot Holders (as defined below), we will purchase Shares on the following basis: ● first, we will purchase Odd Lots (as defined below) of fewer than 100 Shares at the Purchase Price from stockholders who properly tender all of their Shares and who do not properly withdraw them before the Expiration Date. Tenders of less than all of the Shares owned, beneficially or of record, by such Odd Lot Holder will not qualify for this preference; and ● second, after purchasing all Odd Lots that were properly tendered, we will purchase all Shares properly tendered on a pro rata basis...

no_priority = True...perly withdrawn before the Expiration Date is 300,000 or less. If the aggregate number of Shares tendered by Odd Lot Holders exceeds 300,000 then all Shares properly tendered and not properly withdrawn before the Expiration Date by all stockholders, including Odd lot Holders, will be subject to proration. See Section 1. How will the Offer affect the number of Shares outstanding and the number of record holders? As of December 19, 2025, there were 41,084,731 shares of Common Stock issued and outstanding. If the Offer is fully subscribed, we would purchase 300,000 Shares, which would represent approximately 0.7% of the issued and outstandi...

no_priority = True...perly withdrawn before the Expiration Date is 300,000 or less. If the aggregate number of Shares tendered by Odd Lot Holders exceeds 300,000 then all Shares properly tendered and not properly withdrawn before the Expiration Date by all stockholders, including Odd lot Holders, will be subject to proration. See Section 1. How will the Offer affect the number of Shares outstanding and the number of record holders? As of December 19, 2025, there were 41,084,731 shares of Common Stock issued and outstanding. If the Offer is fully subscribed, we would purchase 300,000 Shares, which would represent approximately 0.7% of the issued and outstandi...

price = USD 3.5EX-99 2 exa1-a.htm EX-99 Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH BY Anebulo Pharmaceuticals, Inc. OF UP TO 300,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $3.50 PER SHARE, REPRESENTING AN AGGREGATE PURCHASE PRICE OF UP TO $1,050,000 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON Monday, January 26, 2026, UNLESS THE OFF...

price = USD 3.5EX-99 2 exa1-a.htm EX-99 Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH BY Anebulo Pharmaceuticals, Inc. OF UP TO 300,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $3.50 PER SHARE, REPRESENTING AN AGGREGATE PURCHASE PRICE OF UP TO $1,050,000 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON Monday, January 26, 2026, UNLESS THE OFF...

price = USD 3.5...ed and supplemented, the “Schedule TO”) relating to the tender offer by the Company to purchase for cash up to 300,000 shares of its common stock, par value $0.001 per share, at a purchase price of $3.50 per share, to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal, copies of which...

priority_conflicting = True...and more than 300,000 Shares have been properly tendered and not properly withdrawn prior to the Expiration Date and of such tendered Shares 300,000 or less are tendered by Odd Lot Holders (as defined below), we will purchase Shares on the following basis: ● first, we will purchase Odd Lots (as defined below) of fewer than 100 Shares at the Purchase Price from stockholders who properly tender all of their Shares and who do not properly withdraw them before the Expiration Date. Tenders of less than all of the Shares owned, beneficially or of record, by such Odd Lot Holder will not qualify for this preference; and ● second, after purchasing all Odd Lots that were prope...

priority_conflicting = True...and more than 300,000 Shares have been properly tendered and not properly withdrawn prior to the Expiration Date and of such tendered Shares 300,000 or less are tendered by Odd Lot Holders (as defined below), we will purchase Shares on the following basis: ● first, we will purchase Odd Lots (as defined below) of fewer than 100 Shares at the Purchase Price from stockholders who properly tender all of their Shares and who do not properly withdraw them before the Expiration Date. Tenders of less than all of the Shares owned, beneficially or of record, by such Odd Lot Holder will not qualify for this preference; and ● second, after purchasing all Odd Lots that were prope...

threshold = 100...hares have been properly tendered and not properly withdrawn prior to the Expiration Date and of such tendered Shares 300,000 or less are tendered by Odd Lot Holders (as defined below), we will purchase Shares on the following basis: ● first, we will purchase Odd Lots (as defined below) of fewer than 100 Shares at the Purchase Price from stockholders who properly tender all of their Shares and who do not properly withdraw them before the Expiration Date. Tenders of less than all of the Shares owned, beneficially or of record, by such Odd Lot Holder will not qualify for this preference; and ● second, after purchasing all Odd Lots that were prope...

threshold = 100...hares have been properly tendered and not properly withdrawn prior to the Expiration Date and of such tendered Shares 300,000 or less are tendered by Odd Lot Holders (as defined below), we will purchase Shares on the following basis: ● first, we will purchase Odd Lots (as defined below) of fewer than 100 Shares at the Purchase Price from stockholders who properly tender all of their Shares and who do not properly withdraw them before the Expiration Date. Tenders of less than all of the Shares owned, beneficially or of record, by such Odd Lot Holder will not qualify for this preference; and ● second, after purchasing all Odd Lots that were prope...

txn_type = CONSOLIDATION...balance at March 31, 2025 of $13.2 million. The Special Committee presented its analysis of its strategy and strategic alternatives, which included, potential M&A transactions, raising money as a public and private company and “going private” through either a reverse stock split or a tender offer. The Special Committee noted that as stated above, the Company went public primarily to have access to the public markets for financing purposes; however, the public markets have been very difficult these past few years for small-cap biotech stocks and the Company has been unable to raise significant money from the publ...

txn_type = CONSOLIDATION...balance at March 31, 2025 of $13.2 million. The Special Committee presented its analysis of its strategy and strategic alternatives, which included, potential M&A transactions, raising money as a public and private company and “going private” through either a reverse stock split or a tender offer. The Special Committee noted that as stated above, the Company went public primarily to have access to the public markets for financing purposes; however, the public markets have been very difficult these past few years for small-cap biotech stocks and the Company has been unable to raise significant money from the publ...

txn_type = TENDER_OFFER...cash up to 300,000 shares of its common stock, par value $0.001 per share, at a purchase price of $3.50 per share, to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal, copies of which were attached to the Schedule TO and which, together with any other related materials, as each may be amended or supplemented from time to time, collectively constitute the “Offer.” This Final Amendment is being filed to report the results of the Offer and is intended to satisfy the...

expired_on = 2026-01-26...Information. Item 11 of the Schedule TO is hereby amended and supplemented by adding the following: On January 29, 2026 Anebulo issued a press release announcing the final results of the Offer, which expired at one minute after 11:59 p.m., New York City time, on January 26, 2026. A copy of the press release is filed as Exhibit (a)(1)(I) hereto and is incorporated by reference herein. Item 12. Exhibits. (a)(1)(A)* Offer to Purchase dated December 22, 2025. (a)(1)(B)* Letter of Transmittal. (a)(1)(C)* Notice of Guaranteed Delivery. (a)(1)(D)* Letter to Br...

final_price = 3.5...anuary 27, 2026 (as amended and supplemented, the “Schedule TO”) relating to the tender offer by the Company to purchase for cash up to 300,000 shares of its common stock, par value $0.001 per share, at a purchase price of $3.50 per share, to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal, copies of which were attached to the Schedule TO and which, together with an...

oddlot_filled = YES...” at a purchase price of $3.50 per Share, for an aggregate cost of approximately $1.05 million, excluding fees and expenses relating to the Offer. The Company accepted the Shares on a pro rata basis, except for tenders of “odd lots,” which were accepted in full. The Company has been informed by the Depositary that the final proration factor for the Offer was 3.47392%. The Shares accepted for payment represent approximately 0.73% of the Shares that were outstanding as of January 26, 2026. ● The Company will wire payment for the Shares t...

proration_pct = 3.47392...ses relating to the Offer. The Company accepted the Shares on a pro rata basis, except for tenders of “odd lots,” which were accepted in full. The Company has been informed by the Depositary that the final proration factor for the Offer was 3.47392%. The Shares accepted for payment represent approximately 0.73% of the Shares that were outstanding as of January 26, 2026. ● The Company will wire payment for the Shares to the Depositary for the Offer on January 29, 2026. ● The Depositary will promptly pay for all of the Shares...

tendered = 4907881...t to Rule 13e-3(d)(3) and Rule 13e-4(c)(4): ● The Company has received the final results of the Offer, which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. ● A total of 4,907,881 Shares were validly tendered and not properly withdrawn prior to the expiration of the Offer. ● The Offer was oversubscribed. In accordance with the terms and conditions of the Offer and based on the final count by the Depositary, the Company accepted for payment an aggregate of 300,000 Shares, including 13...